Logo image of BGXX

BRIGHT GREEN CORP (BGXX) Stock Fundamental Analysis

NASDAQ:BGXX - Nasdaq - US10920G1004 - Common Stock - Currency: USD

0.1481  -0.04 (-22.01%)

After market: 0.155 +0.01 (+4.66%)

Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BGXX. BGXX was compared to 195 industry peers in the Pharmaceuticals industry. BGXX has a bad profitability rating. Also its financial health evaluation is rather negative. BGXX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BGXX had negative earnings in the past year.
In the past year BGXX has reported a negative cash flow from operations.
In the past 5 years BGXX always reported negative net income.
In the past 5 years BGXX always reported negative operating cash flow.
BGXX Yearly Net Income VS EBIT VS OCF VS FCFBGXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -62.04%, BGXX is doing worse than 70.26% of the companies in the same industry.
BGXX's Return On Equity of -100.53% is in line compared to the rest of the industry. BGXX outperforms 40.51% of its industry peers.
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROIC N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
BGXX Yearly ROA, ROE, ROICBGXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

BGXX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGXX Yearly Profit, Operating, Gross MarginsBGXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

1

2. Health

2.1 Basic Checks

BGXX has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, BGXX has an improved debt to assets ratio.
BGXX Yearly Shares OutstandingBGXX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M
BGXX Yearly Total Debt VS Total AssetsBGXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

BGXX has an Altman-Z score of -3.41. This is a bad value and indicates that BGXX is not financially healthy and even has some risk of bankruptcy.
BGXX has a Altman-Z score (-3.41) which is comparable to the rest of the industry.
BGXX has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
BGXX's Debt to Equity ratio of 0.05 is in line compared to the rest of the industry. BGXX outperforms 51.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.41
ROIC/WACCN/A
WACCN/A
BGXX Yearly LT Debt VS Equity VS FCFBGXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

BGXX has a Current Ratio of 0.02. This is a bad value and indicates that BGXX is not financially healthy enough and could expect problems in meeting its short term obligations.
BGXX has a worse Current ratio (0.02) than 99.49% of its industry peers.
A Quick Ratio of 0.02 indicates that BGXX may have some problems paying its short term obligations.
BGXX has a Quick ratio of 0.02. This is amonst the worse of the industry: BGXX underperforms 99.49% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
BGXX Yearly Current Assets VS Current LiabilitesBGXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.28% over the past year.
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BGXX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGXX Price Earnings VS Forward Price EarningsBGXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGXX Per share dataBGXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BGXX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIGHT GREEN CORP

NASDAQ:BGXX (9/18/2024, 8:00:00 PM)

After market: 0.155 +0.01 (+4.66%)

0.1481

-0.04 (-22.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2022-11-14/amc
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner Change0%
Ins Owners65.87%
Ins Owner Change0%
Market Cap28.16M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.04%
ROE -100.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-75.05%
ROA(5y)-54.76%
ROE(3y)-129.62%
ROE(5y)-88.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 68.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -3.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)646.55%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y48.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y78.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.91%
OCF growth 3YN/A
OCF growth 5YN/A